Figure 3 | Scientific Reports

Figure 3

From: Tear proteomics reveals the molecular basis of the efficacy of human recombinant nerve growth factor treatment for Neurotrophic Keratopathy

Figure 3

Tear functional proteomics results after 8 weeks of treatment. (A) Interleukin-6 receptor (IL6R) resulted the most significant activated Upstream by comparing proteomics dataset at T0 and T8 timepoint of treatment with rhNGF. (B) Identified proteins related to the activation of IL6R.Colour key and symbols are reported in the Fig. 2. (C) Matrix metalloproteinase-9 (MMP-9) expression in one representative NK patient at T0, T4 and T8 timepoint during therapy. (D) Histograms reporting the mean of six patients of OD pixel intensity in percent of the MMP-9 band (92 kDa). MMP-9 expression in each patient at T0, T4 and T8 is reported in the WBs of Supplementary Fig. S1. Multiple exposure time points, as well as the full-length blots are shown in Figs. S2 and S3. Error bars show the standard error of the mean from six NK patients at the different times of treatment. * means p-value < 0.05, *** means p-value < 0.001 at the Student’s t-test.

Back to article page